Insider selling is not extreme, but the cluster near a debt facility expansion warrants monitoring. Watch for any upcoming disclosure on clinical data or additional financing that might have motivated these sales. If selling continues, it could pressure shares near term.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 1 $21.79entry
- T+1 · 5mo ago +5.87%α +6.01% · $23.07
- T+5 · 4mo ago +9.36%α +9.10% · $23.83
- T+20 · 4mo ago +15.19%α +17.38% · $25.10
- T+60 · 8w ago −24.23%α −27.10% · $16.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three Dyne Therapeutics insiders sold a combined $5.02M in shares over a 6-day window, led by Director Rhodes ($4.9M). CFO Lucera sold a small amount ($48K). The sales follow a recent $50M borrowing under an expanded $400M Hercules debt facility (8-K on 6/17). Total selling represents ~0.14% of market cap, a modest amount that is not alarming given the pre-revenue biotech context.
Key Financial Metrics
Key Facts
- Insider cluster: 3 insiders sold 5 trades totaling $5.02M from June 23-29.
- Director Jason Rhodes sold $5.0M (bulk of sales); CFO Erick Lucera sold $48K.
- Sales follow June 17 debt facility expansion ($50M draw, $400M total capacity).
- Total sales represent ~0.14% of DYN's $3.5B market cap.
Financial Impact
Insider sales of $5.02M, modest relative to $3.5B market cap.
Risk Factors
- Continued insider selling could signal lack of confidence or pre-arranged plans.
- Debt facility increases leverage and secured IP collateral; adverse clinical data could trigger covenant issues.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DYN-1782860743423 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers